MacroGenics, Inc. (NASDAQ:MGNX) has made a 64.64% comeback from a 12-month low price of $9.87. It was seen -6.72% lower, changing the price to $16.25, when the closing bell rang on 5/13/2019. At a recent session, the prices were hovering between $17.04 and $17.82. This company shares are 111.45% off its target price of $34.36 and the current market capitalization stands at $793.49M. The recent change has given its price a -11.46% deficit over SMA 50 and -49.72% deficit over its 52-week high. The stock witnessed -8.45% declines, -23.96% declines and -2.11% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found MGNX’s volatility during a week at 4.92% and during a month it has been found around 5.04%.

MacroGenics, Inc. (MGNX) Top Holders

Institutional investors currently hold around $689 million or 78.9% in MGNX stock. Look at its top three institutional owners: Oppenheimerfunds, Inc. owns $77.46 million in MacroGenics, Inc., which represents roughly 9.76% of the company’s market cap and approximately 11.24% of the institutional ownership. Similar statistics are true for the second largest owner, Blackrock Inc., which owns 3,404,692 shares of the stock are valued at $59.31 million. The third largest holder is Bb Biotech Ag, which currently holds $57.2 million worth of this stock and that ownership represents nearly 7.21% of its market capitalization.

MacroGenics, Inc. 13F Filings

At the end of December reporting period, 78 institutional holders increased their position in MacroGenics, Inc. (NASDAQ:MGNX) by some 7,267,723 shares, 55 decreased positions by 5,412,002 and 17 held positions by 26,887,814. That puts total institutional holdings at 39,567,539 shares, according to SEC filings. The stock grabbed 21 new institutional investments totaling 2,285,540 shares while 14 institutional investors sold out their entire positions totaling 1,799,077 shares.

MacroGenics, Inc. (NASDAQ:MGNX) Insider Trades

Multiple company employees have indulged in significant insider trading. MacroGenics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Fust Matthew K has sold 6,924 shares of MacroGenics, Inc. (MGNX) in the trading session dated Feb. 06, 2019. These shares are worth $203,427 and were traded at $29.38 each. The SEC filing shows that Peters Jeffrey Stuart performed a sale of 68 shares. The General Counsel disposed these shares by way of transaction on Feb. 06, 2019. The company’s shares were given away at $30 per share worth to an income of some $2,040 to the account of Peters Jeffrey Stuart.

Sr VP, BPD & Manufacturing, Spitznagel Thomas, sold 1,770 common shares of MacroGenics, Inc. (MGNX) in the open market. In a transaction dated Feb. 06, 2019, the shares were put up for sale at an average price of $30, raking in a sum of $53,100. After this sale, common shares of MGNX are directly owned by the insider, with total stake valued at $.

In the transaction dated Mar. 12, 2018, a great number of shares sold came courtesy the Sr VP & Chief Business Officer; Risser Eric Blasius disposed a total of 1,000 shares at an average price of $31.08, amounting to approximately $31,080. The insider now directly owns 9,100 shares worth $147,875.

MacroGenics, Inc. (MGNX) Analyst Guide

Several analysts have released their opinion on MacroGenics, Inc. (NASDAQ:MGNX), with 5 analysts believing it is a strong buy. Whereas 3 of them predict the stock is a hold. Also, there are 5 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.85 average brokerage recommendation [T1].